Novogen - Anisina nixed, GDC-0084 on track for Phase II
Novogen’s recent market updates presented mixed news for investors. Recruitment in the Cantrixil Phase I is underway and preparations for the Phase II trial of GDC-0084 in glioblastoma are progressing well, although headline data are now likely in H1 CY20, 12 months later than we initially forecast. Mixed data from preclinical studies have seen development terminated for Anisina, which had been expected to enter the clinic in H217. While the termination of Anisina is disappointing, it is encouraging to see that management is taking a disciplined approach to assessing pipeline products. We now value Novogen between A$86m (A$0.18/share) and A$146m (A$0.30/share) under two different development scenarios for GDC-0084. Major milestones anticipated in 2017 include initiation of a Phase II trial of GDC-0084 and full enrolment in the Cantrixil Phase I.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.